Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Gastroenterology > ECCO 2023 > Letter from the Editor

Letter from the Editor

Editor
Dr Marjolijn Duijvestein, Radboudumc, the Netherlands
Conference
ECCO 2023
    Dear reader,

    In the current report, we would like to reflect on the 2023 Congress of the European Crohn's and Colitis Organisation (ECCO), which took place at the Bella Centre in Copenhagen on March 1-4, 2023. After 2 years of online editions, it was really exciting to hold the entire programme onsite and enjoy face-to-face interaction again. The 2023 Congress was a great success, bringing together 6,754 participants from all continents to exchange ideas, present research findings, and discuss the latest advances in IBD diagnosis and treatment. For delegates who were not able to attend in person, an online platform was arranged to stream the entire Scientific Programme.

    The Scientific Programme's theme was "Sequencing in IBD" and diverse topics, including "Can we do better with current drugs", "Vascular complications in IBD: an overlooked problem", and "Optimising surgical outcomes" were discussed. Highlights of the congress are presented here and include updates on biological and small molecule therapies, IBD in early life, and advances in surgery.

    As we move forward, it is essential that we continue to work together to address the challenges facing the IBD community. The 2023 ECCO Congress served as a reminder of the importance of collaboration and innovation in advancing IBD research and improving patient outcomes. I look forward to meeting again next year in Stockholm and continuing these important discussions.

    Sincerely,

    Marjolijn Duijvestein
    Biography
    Marjolijn Duijvestein works as a gastroenterologist in the IBD team of the Radboudumc in Nijmegen, the Netherlands. In 2012 she obtained her PhD at Leiden University and was trained as a gastroenterologist specialised in IBD disease at the Amsterdam UMC in Amsterdam. As part of her training, she gained experience at the University of California San Diego (UCSD, USA) and performed an internship at Alimentiv (former Robarts Clinical Trials), an academic research organisation dedicated to drug development for IBD. Her clinical activity and research are focused on IBD, in particular clinical and translational research.
    Conflict of Interest Statement: Has served as an advisor for Echo pharma and Robarts Clinical Trials, reports nonfinancial support from Dr Falk Pharma, and received speaker fees from Janssen, Merck & Co., Pfizer, Takeda and Tillotts Pharma. Advisory boards Janssen, Takeda, BMS and Abbvie. 



    Posted on